Abnova Taiwan Corp. (4133) AI Stock Analysis

Abnova Taiwan Corp.

(TWSE:4133)

Select Model

Rating:43Neutral

Price Target:TWD 19.00▼(-5.00% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by deteriorating profitability and negative cash flow, despite an exceptionally strong balance sheet. Weak technical momentum and a relatively high P/E with a low dividend yield further limit the score.

Positive Factors

Very Low LeverageAbnova’s very low leverage and equity-heavy capital structure reduce solvency risk and preserve financial flexibility. This gives the company greater capacity to withstand operating volatility, fund product development, and respond to weaker trading conditions without heavy debt-service pressure.

Negative Factors

Multi-Year Revenue DeclinePersistent revenue contraction across several years points to weakening demand, customer activity, or commercial execution rather than a single temporary fluctuation. Continued top-line decline can reduce operating leverage, constrain investment capacity, and make a durable return to earnings growth more difficult.

Abnova Taiwan Corp. (4133) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.21B
Dividend Yield: 0.56%
Average Volume (3M): 137.19K
Price to Earnings (P/E): 27.0
Beta (1Y): 0.47
Revenue Growth: -4.19%
EPS Growth: ―
Country: TW
Employees: 110
Sector: General
Sector Strength: 55
Industry: Biotechnology

Abnova Taiwan Corp. Business Overview & Revenue Model

Company Description

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring s...

Abnova Taiwan Corp. Financial Statement Overview

Summary

A strong, low-debt balance sheet is outweighed by sharply weaker profitability and cash generation. Revenue and margins declined, the company reported a net loss, and operating and free cash flow turned negative.

Income Statement

25Negative

Balance Sheet

85Very Positive

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	345.45M	351.30M	355.26M	382.05M	411.76M	451.49M
Gross Profit	155.52M	139.87M	163.26M	173.91M	201.43M	197.34M
EBITDA	57.41M	45.66M	103.47M	81.21M	129.60M	79.79M
Net Income	44.87M	-1.14M	61.61M	43.68M	74.84M	28.37M
Balance Sheet
Total Assets	1.35B	1.33B	1.40B	1.36B	1.37B	1.28B
Cash, Cash Equivalents and Short-Term Investments	406.17M	378.71M	448.55M	423.51M	367.91M	307.27M
Total Debt	17.06M	18.50M	24.01M	7.71M	10.88M	8.18M
Total Liabilities	79.68M	70.74M	91.65M	69.42M	82.83M	71.29M
Stockholders Equity	1.27B	1.26B	1.31B	1.29B	1.29B	1.21B
Cash Flow
Free Cash Flow	44.76M	-7.73M	43.13M	47.33M	118.51M	92.04M
Operating Cash Flow	51.47M	-4.19M	50.85M	76.22M	132.37M	92.88M
Investing Cash Flow	-9.63M	-6.22M	19.78M	36.79M	-13.37M	960.00K
Financing Cash Flow	-60.04M	-60.01M	-49.09M	-55.62M	-61.40M	-43.80M

Abnova Taiwan Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4133 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4161	61Neutral	TWD 1.22B	11.45	―	3.32%	7.54%	35.87%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1796	52Neutral	TWD 1.14B	162.76	―	2.50%	7.05%	―
TW:4133	43Neutral	TWD 1.20B	27.03	―	0.56%	-4.19%	―
TW:6578	42Neutral	TWD 1.21B	-51.66	―	2.37%	21.50%	-5.51%

* General Sector Average

Performance Comparison

TW:4133 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4133	Abnova Taiwan Corp.	20.00	-3.47	-14.79%
TW:1796	GeneFerm Biotechnology Co. Ltd.	28.00	-19.13	-40.59%
TW:4161	Bioptik Technology, Inc.	21.10	-4.50	-17.57%
TW:6564	Enimmune corporation	14.90	-6.22	-29.44%
TW:6578	Dabomb Protein Biotech Corporation	17.00	-2.65	-13.49%
TW:7530	Forward Science Corp.	28.40	14.81	109.02%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Abnova Taiwan Corp. AI Stock Analysis